FDA Should Do More To Boost Transparency To Industry, Firms Say
This article was originally published in The Gray Sheet
FDA's plans to improve transparency with industry do not go far enough, device and biotech firms say in recent comments to the agency.
You may also be interested in...
FDA Device Center Analyzes Why It Missed PMA Review Goals
FDA pre-market approval reviews tend to take longer when the medical officer leaves the review team, when clinical trial data issues arise and when companies engage in "excessive" back and forth with FDA during the review process, according to a recent FDA analysis.
FDA Unveils Plan To Boost Transparency To Industry
Included in a new list of things FDA will do to improve its communications with manufacturers is a vow to respond more quickly to industry questions.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.